Patient characteristics
| No. of patients | |
|---|---|
| Institution | |
| Washington University | 35 |
| Syracuse Upstate Medical University/VAMC | 10 |
| Duke University | 8 |
| Durham VAMC | 5 |
| Gender | |
| Males: 37 | |
| Females: 21 | |
| Age (years) | |
| Mean: 65 | |
| Range: 38–83 | |
| Stage | |
| IIIA: 14 | |
| IIIB: 8 | |
| IV: 36 | |
| Tumor histology | |
| Adenocarcinoma: 18 | |
| Adenosquamous: 2 | |
| Large cell neuroendocrine: 2 | |
| Large cell: 19 | |
| Squamous: 17 | |
| No. of patients | |
| Chemotherapy given | |
| Carboplatin + paclitaxel | 29 |
| Carboplatin + gemcitabine | 8 |
| Carboplatin + vinorelbine | 5 |
| Cisplatin + etoposide | 1 |
| Gemcitabine + docetaxel | 2 |
| Gemcitabine + irinotecan | 1 |
| Vinorelbine + docetaxel | 2 |
| Gemcitabine | 4 |
| Vinorelbine | 4 |
| Paclitaxel | 2 |
| Distribution of responses | |
| PR: 10 | |
| Stable: 29 | |
| Progression: 19 | |
| Status at last follow-up | |
| Alive with tumor: 23 | |
| Dead of tumor: 35 | |
| Follow-up time (months) | |
| Median: 8.1 | |
| Range: 1.3–20.6 |